Resapp Health : Appendix 3B

Appendix 3B

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

RESAPP HEALTH LIMITED

ABN

51 094 468 318

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Director Incentive Options

1 +Class of +securities issued or to be issued

14.6 million Director Incentive Options

1. Number of +securities issued or to be issued (if known) or maximum number which may be issued

   7.2 million Tranche 1 Director Incentive Options exercisable at $0.45; expiring 10 November 2019; and

   7.4 million Tranche 2 Director Incentive Options exercisable at $0.75; expiring 10 November 2019.

2. Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid

   +securities, the amount

   outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

   No - Options will convert into ordinary shares.

3. Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

   If the additional +securities do not rank equally, please state:

   • the date from which they do

   • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

   • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5	Issue price or consideration	Director Incentive Options	issued as partial
consideration for services	provided to the
Company as set out in the	Notice of Annual
General Meeting 2016.

Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company, as approved by Shareholders at the Annual General Meeting held on 2 November 2016.

6 Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Yes

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

2 November 2016

6b The date the security holder resolution under rule 7.1A was passed

Nil

6c Number of +securities issued without security holder approval under rule 7.1

+ See chapter 19 for defined terms.

Appendix 3B Page 2 04/03/2013

Nil

6d Number of +securities issued with security holder approval under rule 7.1A

Nil

6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

14.6 million Director Incentive Options

6f Number of +securities issued under an exception in rule 7.2

Not applicable

6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the

+issue date and both values.

Include the source of the VWAP calculation.

Not applicable

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Listing Rule 7.1 - 98,068,440 Listing Rule 7.1A - 65,378,960

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

10 November 2016

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Number	+Class
594,164,603	Fully paid ordinary shares

8 Number and +class of all

+securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
59,624,999	Fully paid ordinary shares
(escrowed to 14 July 2017)
38,437,500	Performance Shares converting
on a 1:1 basis upon the
achievement of milestone
(escrowed to 14 July 2017)
55,312,500	Performance Shares converting
on a 1:1 basis upon the
achievement of milestone
2,437,500	Unlisted Options ($0.026; 31 Dec
2016)
2,812,500	Unlisted Options ($0.026; 31 Dec
2016) - escrowed to 14 July 2017
5,000,000	Incentive Options ($0.025; 2 July
2020)
5,000,000	Incentive Options ($0.05; 2 July
2020)
10,000,000	Incentive Options ($0.10; 2 July
2020)
3,000,000	Incentive Options ($0.05; 22
September 2020)
2,000,000	Incentive Options ($0.10; 22
September 2020)
4,500,000	Unlisted Options ($0.28; 29
April 2019) escrowed for 12
months to 29 April 2017.
1,866,667	Unlisted Options ($0.30; 29 April
2019) escrowed for 12 months to
29 April 2017.
2,000,000	Employee Incentive Options
($0.45; 16 September 2019)
pursuant to the terms of the
ESOP
2,000,000	Consultancy Incentive Options
($0.45; 16 September 2019)
2,000,000	Consultancy Incentive Options
($0.75; 16 September 2019)
7,200,000	Director Incentive Options
($0.45; 10 November 2019)
7,400,000	Director Incentive Options
	($0.75; 10 November 2019)

Number and +class of all

+securities not quoted on ASX (including the +securities in section 2 if applicable)

+ See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013